You just read:

AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis

News provided by

AbbVie

Feb 19, 2019, 08:31 ET